You are here » Home » Companies » Company Overview » Ankur Drugs & Pharma Ltd

Ankur Drugs & Pharma Ltd.

BSE: 531683 Sector: Health care
NSE: ANKURDRUGS ISIN Code: INE238D01012
BSE LIVE 05:30 | 01 Jan Stock Is Not Traded.
NSE LIVE 00:00 | 10 Sep Stock Is Not Traded.
OPEN
PREVIOUS CLOSE
VOLUME
52-Week high 0.00
52-Week low 0.00
P/E
Mkt Cap.(Rs cr)
Buy Price
Buy Qty
Sell Price
Sell Qty
OPEN
CLOSE
VOLUME
52-Week high 0.00
52-Week low 0.00
P/E
Mkt Cap.(Rs cr)
Buy Price
Buy Qty
Sell Price
Sell Qty

Ankur Drugs & Pharma Ltd. (ANKURDRUGS) - Company History

Ankur Drugs and Pharma Ltd is engaged in contract manufacturing of pharmaceuticals formulations. The company has three manufacturing units: two in Himachal Pradesh and one in Daman. Its business segment includes pharmaceutical formulations in the form of tablets, capsules, liquid orals, oral powder, dry syrups, ointments, insta use suspension, form fill and seal (FFS), liquid injectables and dry powder injectables. Its clients include Ranbaxy Laboratories Limited, Cipla Limited, Sandoz Private Limited, Abbott India Limited, USV Limited, Plizer Limited and Sanofi Aventis.The company is a public limited company listed at Bombay Stock Exchange and National Stock Exchange of India Limited. The company was incorporated in the year 1995. Ankur has to its credit several distinctions. It's in the forefront of contract manufacturing with India's leading and multinational pharmaceutical companies. Ankur's first plant is situated at Daman, which is having dedicated block for General and Betalactum products in oral dosage form. The Company has set-up two plants spread across 'dimensions' at Himachal Pradesh in excise and pollution free zone, amongst lush green surroundings. The main object behind setting up two units was to cater Domestic and International Market. The company's 400 different formulations of various dosage forms i.e. Tablets, Capsules, Dry Syrups, Liquid Orals, Injectables, Oinments, etc. are currently manufactured in Ankur's multi location manufacturing facilities. Company has already received WHO GMP Certification for both Units at Himachal Pradesh. As of March 31, 2010, it had installed capacities of 15,720 million tablets, 2,886 million capsules and 300 million effervescent tablets. During the fiscal year ended March 31, 2010 (fiscal 2010), it had a production of 9,800 million tablets, 2,090 million capsules and 157 million effervescent tablets. During fiscal 2010, it had in-house developed mosquito repellant patch from ayurvedic formulations.

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard